TITLE

Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice

AUTHOR(S)
Gupta, R. K.; Loveday, Clive; Kalidindi, U.; Lechelt, M.; Skinner, Celia; Orkin, Chloe
PUB. DATE
September 2007
SOURCE
International Journal of STD & AIDS;Sep2007, Vol. 18 Issue 9, p630
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Escalating drug resistance in treatment-experienced HIV-1-infected patients has made management increasingly difficult. In clinical trials, tipranavir (TPV) has produced potent and durable responses in such patients, although experience in clinical cohorts is limited. A retrospective clinical case review was undertaken of triple-class experienced HIV-1-infected patients receiving optimized boosted TPV-containing regimens and T20 with up to 108 weeks follow-up. Antiretroviral therapy (ART) resistance profiles were characterized using International Aids Society (IAS)-USA scoring and 'TPV resistance score' (TPV-RS) at baseline and failure. Five of 12 patients had undetectable virus (<50 copies/mL) after median 84 weeks (range 60–108), and 1/12 < had 700 copies/mL after 40 weeks. Six of 12 patients failed after 36 (range 12–48) weeks and were more likely to have ≥3 TPV-RS mutations than non-failures (P = 0.06). Presence of a major IAS-USA mutation at baseline was strongly associated with absence of a 1 log viral load drop at 24 weeks (P = 0.02). TPV-containing regimens showed impressive efficacy and tolerability in this heavily experienced cohort.
ACCESSION #
26284796

 

Related Articles

  • Nelfinavir: A Review of its Use in the Management of HIV Infection. Perry, Caroline M.; Frampton, James E.; McCormack, Paul L.; Siddiqui, M. Asif A.; Cvetkovi0107;, Risto S. // Drugs;2005, Vol. 65 Issue 15, p2209 

    Nelfinavir (Viracept®) is an orally administered protease inhibitor. In combination with other antiretroviral drugs (usually nucleoside reverse transcriptase inhibitors [NRTIs]), nelfinavir produces substantial and sustained reductions in viral load in patients with HIV infection. Nelfinavir...

  • Initiating Highly Active Antiretroviral Therapy with Newer Protease Inhibitors Is Associated with Better Survival Compared to First-Generation Protease Inhibitors or Nevirapine. Crane, Heidi M.; Van Rompaey, Stephen E.; Kitahata, Mari M. // AIDS Patient Care & STDs;Dec2007, Vol. 21 Issue 12, p920 

    The high prevalence of comorbidity among HIV-infected patients in care such as hepatitis C virus (HCV) coinfection and mental illness may contribute to increased toxicity and decreased adherence to highly active antiretroviral therapy (HAART). Newer HAART regimens have less toxicity and better...

  • Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Antiretroviral- Naive HIV- Infected Patients. Jemsek, Joseph G.; Arathoon, Eduardo; Arlotti, Massimo; Perez, Carlos; Sosa, Nestor; Pokrovskiy, Vadim; Thiry, Alexandra; Soccodato, Michael; Noor, Mustafa A.; Giordano, Michael // Clinical Infectious Diseases;1/15/2006, Vol. 42 Issue 2, p273 

    Background. Protease inhibitor treatment of human immunodeficiency virus (HIV)-infected individuals has been linked to the development of lipodystrophy. The effects of atazanavir on body fat distribution and related metabolic parameters were examined in antiretroviral-naive patients. Methods....

  • Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. F&ätkenheuer, Gerd; Pozniak, Anton L.; Johnson, Margaret A.; Plettenberg, Andreas; Staszewski, Schlomo; Hoepelman, Andy I. M.; Saag, Michael S.; Goebel, Frank D.; Rockstroh, Jürgen K.; Dezube, Bruce J.; Jenkins, Tim M.; Medhurst, Christine; Sullivan, John F.; Ridgway, Caroline; Abel, Samantha; James, Ian T.; Youle, Mike; van der Ryst, Elna // Nature Medicine;Nov2005, Vol. 11 Issue 11, p1170 

    We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10–15 d, with a mean reduction of...

  • Lead Optimisation: Improving the Affinity of the Antiretrovirals Nelfinavir and Amprenavir for HIV-1 Protease. Fernandes, P. A.; Ara�jo, M.L. A.C.; Barbosa, A. J.M.; Alves, C. N.; Ferreira, Z. Q.; R.-N. Gonzalez, C.; C. Lima, C.F. R.A.; Loureiro, S. I.E.; Magalhaes, J. M.T.; Maia, F. C.; Moura, S. A.; Peredo, E.M. M.; Perez, M.A. S.; Rodrigues, T.A. Q.; Pessoa, A.M.; da Silva, C.A. M.; da Silva, J.P. A.; Ramos, M. J. // Letters in Drug Design & Discovery;Aug2006, Vol. 3 Issue 6, p383 

    Nelfinavir (Viracept�, Pfizer), and Amprenavir (Ageneraze�, GlaxoSmithKline) are potent bioavailable inhibitors of the enzyme Protease (PR) of the Human Immunodeficiency V�rus-1 (HIV-1), which have been developed by consistent structure-based drug design projects, and have been...

  • Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen. Hatano, Hiroyu; Hunt, Peter; Weidler, Jodi; Coakley, Eoin; Hoh, Rebecca; Liegler, Teri; Martin, Jeffrey N.; Deeks, Steven G. // Clinical Infectious Diseases;11/15/2006, Vol. 43 Issue 10, p1329 

    Background. Many treatment-experienced, HIV-infected patients who have limited therapeutic options for complete viral suppression continue to receive a partially suppressive treatment regimen pending the availability of at least 2 new antiretroviral drugs. The major risk of this approach is...

  • Effects of HIV Antiretroviral Therapy on Sexual and Injecting Risk-Taking Behavior: A Systematic Review and Meta-analysis. Doyle, Joseph S.; Degenhardt, Louisa; Pedrana, Alisa E.; McBryde, Emma S.; Guy, Rebecca J.; Stoové, Mark A.; Weaver, Emma R.; Grulich, Andrew E.; Lo, Ying-Ru; Hellard, Margaret E. // Clinical Infectious Diseases;Nov2014, Vol. 59 Issue 10, p1483 

    This systematic review and meta-analysis of 58 studies found that antiretroviral therapy is not associated with increased sexual or injecting risk-taking behavior among HIV-infected individuals undergoing treatment.Background. Increased global access and use of antiretroviral therapy (ART) for...

  • Boosted Darunavir for Treatment-Experienced Patients.  // Clinical Infectious Diseases;9/1/2007, Vol. 45 Issue 5, pvi 

    The article discusses the study "Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomized trials," by B. Clotet and colleagues. In the study, the researchers gave the...

  • Decreasing HIV Drug Resistance in the United Kingdom.  // Clinical Infectious Diseases;9/1/2007, Vol. 45 Issue 5, pvi 

    The article discusses the study "A decreasing prevalence of antiretroviral drug resistance in the UK: evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom." In the study, the researchers conducted analysis of major resistance mutations to determine time-dependent...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics